Ingevity CorpNGVT
Price$71.09Intrinsic value$52.9126% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $1.2B-3.3% YoYTTM through 30 Jun 2026
Net Income $54MTTM through 30 Jun 2026
Free Cash Flow $154.9MTTM through 30 Jun 2026

Margins

Current
Gross Margin45.1%
EBITDA Margin11.9%
Operating Margin26.6%
Net Margin4.7%

Returns

-401.0%ROE
-9.5%ROA
4.7%ROIC

Balance Sheet Health

Debt / Equity31.03x
Current Ratio1.61x
Net Debt$1B
Cash & Equivalents$97.4M

Quality Metrics

Altman Z-Score2.44
Piotroski F-Score8 / 9
FCF Margin13.3%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $1.2B
Diluted EPS$1.52TTM
'19'20'21'22'23'24'25
FY2025: $-4.61

Dividend

No dividend

Capital Allocation

R&D Spend$27.2M
Capex Intensity4.8%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.